Our mission is to treat osteoarthritis and get people moving without pain.
About
Sparta Biomedical is creating the first-of-its-kind chemically engineered cartilage platform, Hyalos. The degeneration of cartilage between joints can cause significant personal, economic, and societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time. We are developing cartilage-like implants for the all of the important joints in the body.
solving a massive problem that affects the world’s population
address cartilage degeneration
intersection of chemistry, mechanical engineering, biology
Hyalos is a Multi-Indication Platform
Shoulder
Thumb
Partial knee
Ormi™
Patella
Elbow
Hip
Trochlea
Ankle
Toe
Leadership Team
We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas, and are driven by a common purpose; we seek to advance the standard of care for osteoarthritis and get people moving again without pain.
Travis Entrop
Senior R&D Engineer
Clinical Need
Knee cartilage degeneration
0M
Adults with osteoarthritis
0M
Annual visits as a result of knee pain
0K
Knee Cartilage repair procedures by 2030
We all have friends and family who are suffering from knee pain and limited range of motion. This is not only a problem locally, but globally. Over 500M suffer from osteoarthritis (OA). There are 16M visits in the US specifically for knee symptoms. In addition, there are hundreds of thousands osteochondral repairs per year. Unfortunately, there is a high percentage of patients who have a revision within two years. In addition, there are several million people getting a total knee replacement each year. A third of them were considered inappropriate candidates for this intervention. This issue also afflicts active military. Limited duty days exceed 1M after chondral procedures. One in three veterans have OA. The overall prevalence of knee cartilage lesions in high performance athletes is almost 40%.
Our Approach
The condition of any given joint is not just a result of chronological age, but also biological age - prior injury, daily routine, profession, and diet. Hyalos, our proprietary bionic cartilage, renders biological age irrelevant. Unlike cartilage regeneration technologies which take months, if not years, to fully regenerate cartilage, Hyalos replicates the physical properties of native human hyaline cartilage immediately. With optimized geometry based on anatomical locations, our technology has the potential to allow us to precisely and effectively address the needs of patients afflicted with osteoarthritis and cartilage defects, providing patients with immediate pain reduction and full range of motion, resulting in a quality of life they deserve. The OrmiTM implant, a Breakthrough Device, was created by combining Hyalos with an osseointegrative titanium base. OrmiTM is intended to treat chondral and osteochondral lesions of the femoral condyle.
The Treatment Gap
Current technologies and treatments for cartilage defects have severe limitations. Click here to learn about the different surgical treatments available, and how they fall short next to Ormi™.
Read MoreClinical Benefit
A Target Product Profile (TPP) is a set of outcomes that focuses our efforts on building a solution that meaningfully improves that standard of care. Along with satisfying many safety requirements, we set a high bar on those outcomes that matter most for patients. Our TPP is unmatched by existing treatments and technologies in development. We believe this will instill confidence in surgeons as they help their patients quickly resume their daily routines and while knowing many productive years lay ahead. Surgeons can take comfort in knowing their patients will quickly resume their routines and have highly productive lives many years to come.
| Biologic / Cartilage Regeneration* | Ormi™ | |
|---|---|---|
| Dependent on patient's biology | Yes | No |
| Full weight bearing / Pain reduction | Several weeks | 1–2 days |
| Achieve full range of motion | Several days/weeks | Few days |
| Return to biking, jogging, sports | 6–24 months | Within few weeks |
| Durability | 5 years | At least 10yrs |
*examples: microfracture, scaffolds plus microfracture, technologies in development
In The News
Sep 17, 2024
Sparta Biomedical Reports Treatment of First Patients with Breakthrough Device, Ormi
Apr 16, 2024
Plug and Play Announces Inaugural Batch of Startups Selected for their Medtech Program
Oct 17, 2023
Sparta Biomedical Recognized with the MedTech Innovator Execution Award and the AdvaMed Accel Virginia Shimer Rybski Memorial Award
Press Releases
Stiff, Achy Knees? Lab-Made Cartilage Gel Outperforms the Real ThingAuthors: Robin A. SmithReference: Duke University
A Synthetic Hydrogel Composite with the Mechanical Behavior and Durability of CartilageAuthors: Feichen Yang, Jiacheng Zhao, William J. Koshut, John Watt, Jonathan C. Riboh, Ken Gall, Benjamin J. WileyReference: Wiley Online Library (2020)
High-Strength Hydrogel Attachment through Nanofibrous ReinforcementAuthors: Jiacheng Zhao, Alina Kirillova, Cambre N. Kelly, Heng Xu, William J. Koshut, Feichen Yang, Ken Gall, Benjamin J. WileyReference: Wiley Online Library (2020)
A Synthetic Hydrogel Composite with a Strength and Wear Resistance Greater than CartilageAuthors: Jiacheng Zhao, Huayu Tong, Alina Kirillova, William J. Koshut, Andrew Malek, Natasha C. Brigham, Matthew L. Becker, Ken Gall, and Benjamin J. WileyReference: Wiley Online Library (2022)
Contact Us
* (GBD 2021 Osteoarthritis Collaborators (2023). Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. Rheumatology, 5(9), e508–e522. GBD 2021 Osteoarthritis Study